Inflammation and lung disease in the neonatal period

NeoReviews

Volumn 9, Issue 10, 2008, Pages

  Yoder, Bradley A ^a   Albertine, Kurt H ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77149143269     PISSN: None     EISSN: 15269906     Source Type: Journal    
DOI: 10.1542/neo.9-10-e447     Document Type: Article

References (54)

1. Bourbon J, Boucherat O, Chailley-Heu B, Delacourt C. Control mechanisms of lung alveolar development and their disorders in bronchopulmonary dysplasia. Pediatr Res. 2005;57:38R-46R
2. Demayo F, Minoo P, Plopper C, Schugar L, Shannon J, Torday J. Mesenchymal-epithelial interactions in lung development and repair: are modeling and remodeling the same process? Am J Physiol Lung Cell Mol Physiol. 2002;283:L510-L517
3. Groenman F, Unger SPM. The molecular basis for abnormal human lung development. Biol Neonate. 2005;87:164-177
4. Jankov R, Tanswell A. Growth factors, postnatal lung growth and bronchopulmonary dysplasia. Paediatr Respir Rev. 2004; 5(suppl A):S265-S275
5. Beaveja R, Christou H. Pharmacological strategies in the prevention and management of bronchopulmonary dysplasia. Semin Perinatol. 2006;30:209-218
6. Kallapur S, Jobe A. Contribution of inflammation to lung injury and development. Arch Dis Child Fetal Neonatal Ed. 2006;91: F132-F135
7. Speer C. Inflammation and bronchopulmonary dysplasia: a continuing story. Semin Fetal Neonatal Med. 2006;11:354-362
8. Coalson J. Pathology of bronchopulmonary dysplasia. Semin Perinatol. 2006;30:179-184
9. Kumar A, Takada Y, Boriek A, Aggarwal B. Nuclear factor-kappa B: its role in health and disease. J Mol Med. 2004;82:434-448
10. Bonizzi G, Karin M. The two NF-kappa B activation pathways and their role in innate and adaptive immunity. Trends Immunol. 2004;25:280-288
11. Park G, Christman J. Nuclear factor kappa B is a promising therapeutic target in inflammatory lung disease. Curr Drug Targets. 2006;7:661-668
12. Becker J, Delayre-Orthez C, Frossard N, Pons F. Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases? Fundament Clin Pharmacol. 2006;20:429-447
13. Genolet R, Wahli W, Michalik L. PPARs as drug targets to modulate inflammatory responses? Curr Drug Targets Inflamm Allergy. 2004;3:361-375
14. Muraoka R, Bushdid P, Brantley D, Yull F, Kerr L. Mesenchymal expression of nuclear factor-kappa B inhibits epithelial growth and branching in the embryonic chick lung. Dev Biol. 2000;225:322-338
15. Araya J, Cambier S, Morris A, Finkbeiner W, Nishimura S. Integrin-mediated transforming growth factor-beta activation regulates homeostasis of the pulmonary epithelial-mesenchymal trophic unit. Am J Pathol. 2006;169:405-415
16. Pittet J-P, Griffiths M, Geiser T, et al. TGF-beta is a critical mediator of acute lung injury. J Clin Invest. 2001;107:1537-1544
17. Londhe V, Nguyen H, Jeng J, et al. NF-kappa B induces lung maturation during mouse lung morphogenesis. Dev Dyn. 2008; 237:328-338
18. Bellusci S, Henderson R, Winnier G, Oikawa T, Hogan B. Evidence from normal expression and targeted misexpression that bone morphogenetic protein (BMP-4) plays a role in mouse embryonic lung morphogenesis. Development. 1996;122:1693-1702
19. Nakashima H, Nakamura M, Yamaguchi H, et al. Nuclear factor-kappa B contributes to hedgehog signaling pathway activation through sonic hedgehog induction in pancreatic cancer. Cancer Res. 2006;66:7041-7049
20. Yang G, Abate A, George A, Weng Y-H, Dennery P. Maturational differences in lung NF-kappa B activation and their role in tolerance to hyperoxia. J Clin Invest. 2004;114:669-678
21. Diepernik H, Blackwell T, Prince L. Hyperoxia and apoptosis in developing mouse lung mesenchyme. Pediatr Res. 2006;59: 185-190
22. Prince L, Okoh V, Moninger T, Matalon S. Lipopolysaccharide increases alveolar type II cell number in fetal mouse lungs through toll-like receptor 4 and NF-kappa B. Am J Physiol Lung Cell Mol Physiol. 2004;287:L999-L1006
23. Bourbia A, Cruz M, Rozycki H. NF-kappa B in tracheal lavage fluid from intubated premature infants: association with inflammation, oxygen, and outcome. Arch Dis Child Fetal Neonatal Ed. 2006;91:F36-F39
24. Cheah F-C, Winterbourn C, Darlow B, Mocatta T, Vissers M. Nuclear factor kappa B activation in pulmonary leukocytes from infants with hyaline membrane disease: associations with chorioamnionitis and Ureaplasma urealyticum colonization. Pediatr Res. 2005;57: 616-623
25. Cao L, Qian L-L, Zhu Y-R, Guo C-B, Gong X-H, Sun B. Regulation of activity of nuclear factor-kappa B and activator protein-1 by nitric oxide, surfactant and glucocorticoids in alveolar macrophages from piglets with acute lung injury. Acta Pharmacol Sin. 2003;24:1316-1323
26. Li Y-H, Yan Z-Q, Brauner A, Tullus K. Activation of macrophage nuclear factor-kappa B and induction of inducible nitric oxide synthase by LPS. Respir Res. 2002;3:23-29
27. Li Y-H, Yan Z-Q, Jensen J, Tullus K, Brauner A. Activation of nuclear factor kappa B and induction of inducible nitric oxide synthase by Ureaplasma urealyticum in macrophages. Infect Immun. 2000;68:7087-7093
28. Hancox R, Stevens D, Adcock I, Barnes P, Taylor D. Effects of inhaled beta agonist and corticosteroid treatment on nuclear transcription factors in bronchial mucosa in asthma. Thorax. 1999;54: 488-492
29. Ito K, Charron C, Adcock I. Impact of protein acetylation in inflammatory lung diseases. Pharm Therapeutics. 2007;116: 249-265
30. Aghai Z, Kumar S, Farhath S, et al. Dexamethasone suppresses expression of nuclear factor-kappa B in the cells of tracheobronchial lavage fluid in premature neonates with respiratory distress. Pediatr Res. 2006;59:811-815
31. Aghai Z, Kode A, Saslow J, et al. Azithromycin suppresses activation of nuclear factor-kappa B and synthesis of proinflammatory cytokines in tracheal aspirate cells from premature infants. Pediatr Res. 2007;62:483-488
32. Knutson S, Chyla B, Amann J, Bhaskara S, Huppert S, Hiebert S. Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks. EMBO J. 2008;27:1017-1028
33. Shearer B, Billin A. The next generation of PPAR drugs: do we have the tools to find them? Biochim Biophys Acta. 2007;2007: 1082-10893
34. Standiford T, Keshamouni V, Reddy R. Peroxisome proliferator-activated receptor-gamma as a regulator of lung inflammation and repair. Proc Am Thorac Soc. 2005;2:226-231
35. Torday J, Rehan V. Developmental cell/molecular biologic approach to the etiology and treatment of bronchopulmonary dysplasia. Pediatr Res. 2007;62:2-7
36. Torday J, Torres E, Rehan V. The role of fibroblast transdifferentiation in lung epithelial cell proliferation, differentiation and repair in vitro. Pediatr Pathol Mol Med. 2003;22:189-207
37. Sanchez-Esteban J, Tsai S, Sang J, Qin J, Torday J, Rubin L. Effects of mechanical forces on lung-specific gene expression. Am J Med Sci. 1998;316:200-204
38. Torday J, Rehan V. Stretch-stimulated surfactant synthesis is coordinated by the paracrine actions of PTHrP and leptin. Am J Physiol Lung Cell Mol Physiol. 2002;283:L130-L135
39. Simon D, Arikan M, Srisuma S, et al. Epithelial cell PPARgamma contributes to normal lung maturation. FASEB J. 2006;20: 1507-1509
40. Rehan V, Torday J. Lower parathyroid hormone-related protein content of tracheal aspirates in very low birth weight infants who develop bronchopulmonary dysplasia. Pediatr Res. 2006;60:216-220
41. Rehan V, Dargan-Batra S, Wang Y, et al. A paradoxical temporal response of the PTHrP/PPAR-gamma signaling pathway to lipopolysaccharide in an in vitro model of the developing rat lung. Am J Physiol Lung Cell Mol Physiol. 2007;293:L182-L190
42. Berry E, Keelan J, Helliwell R, Gilmour R, Mitchell M. Nanomolar and micromolar effects of 15-deoxy-delta12,14-prostaglandin J2 on amnion-derived WISH epithelial cells: differential roles of peroxisome proliferator-activated receptors gamma and delta and nuclear factor kappa B. Mol Pharmacol. 2005;68:169-178
43. Lappas M, Permezel M, Rice G. 15-deoxy-delta12,14-prostaglandin J2 and troglitazone regulation of the release of phospholipids metabolites, inflammatory cytokines and proteases from human gestational tissues. Placenta. 2006;27:1060-1072
44. Lappas M, Rice G. The role and regulation of the nuclear factor kappa B signalling pathway in human labour. Placenta. 2007;28: 543-556
45. Lindstrom T, Bennett P. 15-deoxy-delta12,14-prostaglandin J2 inhibits interleukin-1 beta-induced nuclear factor-kappa B in human amnion and myometrial cells: mechanisms and implications. J Clin Endocrinol Metab. 2005;90:3534-3543
46. Sawada H, Mitani Y, Maruyama J, et al. A nuclear factor-kappa B inhibitor pyrrolidine dithiocarbamate ameliorates pulmonary hypertension in rats. Chest. 2007;132:1265-1274
47. Hart C. The role of PPAR-gamma in pulmonary vascular disease. J Investig Med. 2008;56:518-521
48. Crossno JJ, Garat C, Reusch J, et al. Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling. Am J Physiol Lung Cell Mol Physiol. 2007;292:L885-L897
49. Goldenberg R, Hauth J, Andrews W. Intrauterine infection and preterm delivery. N Engl J Med. 2000;342:1500-1507
50. Lindstrom T, Bennett P. The role of nuclear factor kappa B in human labour. Reproduction. 2005;130:569-581
51. Lappas M, Permezel M, Georgiou H, Rice G. Nuclear factor kappa B regulation of proinflammatory cytokines in human gestational tissues in vitro. Biol Reprod. 2002;67:668-673
52. Lappas M, Permezel M, Rice G. Advanced glycation end products mediate pro-inflammatory actions in human gestational tissues via nuclear factor-kappa B and extracellular signal-regulated kinase 1/2. J Endocrinol. 2007;193:269-277
53. Dunn-Albanese L, Ackerman W, Xie Y, Iams J, Kniss D. Reciprocal expression of peroxisome proliferator-activated receptor-gamma and cyclooxygenase-2 in human term parturition.AmJ Obstet Gynecol. 2004;190:809-816
54. Hillman N, Moss T, Nisos IK, et al. Toll-like receptors and agonist response in the developing fetal sheep lung. Pediatr Res. 2008;63:388-393